Dr. Serafin Morales | Oncologia | Lifetime Achievement Award

Arnau De Vilanova De Lleida, Spain

Author Profile

Early Academic Pursuits

Serafin Morales Murillo embarked on his academic journey with a degree in Medicine and Surgery from Universitat Autònoma de Barcelona in 1987. He further specialized in Medical Oncology, receiving a higher degree from Hospital Valle de Hebrón de Barcelona in 1991. His thirst for knowledge led him to pursue a Doctorate in the Official Postgraduate Program in Health Sciences and Biomedicine from the University of Lleida, culminating in 2015 with a thesis titled "Cáncer de mama: Utilidad pronóstica de los Perfiles de Expresión Proteica en pacientes con tumor residual viable (>1.0cm) tras Quimioterapia adyuvante," supervised by Antonio Llombart Llusac and earning the distinction of "Cum Laude."

Professional Endeavors

He commenced his professional journey as a MEDICO ADJUNTO at Hospital Arnau de Vilanova in 1991, where he continued to serve until 2013. Subsequently, he assumed the role of JEFE DE SECCIÓN at the same institution from March 2023, marking his dedication to the field of oncology for over three decades.

Contributions and Research Focus

Throughout his career, Morales Murillo has exhibited a profound commitment to advancing oncological research and patient care. Notable among his research endeavors are projects exploring the prognostic utility of circulating DNA in localized luminal breast cancer and the study of HER2 biomarkers in plasma and tumor tissue as predictors of response in neoadjuvant treatment for HER2+++ breast cancer.

Accolades and Recognition

His contributions have not gone unnoticed, as evidenced by his induction into esteemed scientific societies and professional associations such as SOLTI, GEICAM, and the Spanish Society of Medical Oncology (SOCIEDAD ESPAÑOLA DE ONCOLOGIA MEDICA), where he has actively contributed since 1991.

Impact and Influence

His work has left a lasting impact on the field of oncology, with his research paving the way for improved prognostic tools and treatment strategies in breast cancer. His dedication to academic excellence and patient-centric care has earned him the respect and admiration of peers and patients alike.

Legacy and Future Contributions

As he continues to push the boundaries of oncological research and patient care, Serafin Morales Murillo's legacy is one of unwavering dedication and profound impact. With a focus on improving outcomes and quality of life for cancer patients, he remains committed to shaping the future of oncology through his ongoing contributions and leadership in the field.


A total of  6948 citations for his publications, demonstrating the impact and recognition of his research within the academic community.

  • Citations             6948
  • h-index               34
  • i10-index            113

Notable Publications 

Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
A Chan, B Moy, J Mansi, B Ejlertsen, FA Holmes, S Chia, H Iwata, ...
(184) 2021

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 …
SM Swain, D Miles, SB Kim, YH Im, SA Im, V Semiglazov, E Ciruelos, ...
(546) 2020

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
(624) 2017

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer …
A Llombart-Cussac, J Cortés, L Paré, P Galván, B Bermejo, N Martínez, ...
(314) 2017

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 …
IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ...

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga, X Carbonell, NJ Castañeda-Soto, M Clemens, M Green, ...
(548) 2005

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non–small-cell lung cancer: A Spanish Lung Cancer Group phase III …
V Alberola, C Camps, M Provencio, D Isla, R Rosell, C Vadell, I Bover, ...
(266) 2003

Pathogenesis of Salmonella enteritidis infection in laying chickens. I. Studies on egg transmission, clinical signs, fecal shedding, and serologic responses
HL Shivaprasad, JF Timoney, S Morales, B Lucio, RC Baker
(277) 1990



Serafin Morales | Oncologia | Lifetime Achievement Award

You May Also Like